Macitentan
Who holds supplier records for Macitentan? 14 organisations hold a current record for Macitentan: an active US FDA Type II Drug Master File. Recorded organisation countries for current records: India (8), China (5) and Netherlands (1).
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Macitentan: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/macitentan
Reading the evidence
- 14 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- 7 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Macitentan expires 18 Oct 2029. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (14)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Macitentan. Country is the organisation's recorded country, not necessarily the manufacturing site.
- Alembic Pharmaceuticals LimitedIndia Company GMP cert on recordActive DMF 31664 · latest filing Apr 2017
- APITORIA PHARMA PRIVATE LTDIndia Company GMP cert on recordActive DMF 31749 · latest filing May 2017
- HONOUR LAB LTDIndia Company GMP cert on recordActive DMF 31213 · latest filing Jan 2017
- Laurus Labs LimitedIndia Company GMP cert on recordActive DMF 31957 · latest filing Sept 2017
- MATRIX PHARMACORP PRIVATE LTDIndiaActive DMF 30969 · latest filing Sept 2016
- MSN LIFE SCIENCES PRIVATE LIMITEDIndia Company GMP cert on recordActive DMF 30212 · latest filing Jan 2016
- RAKS PHARMA PVT LTDIndiaActive DMF 31179 · latest filing Dec 2016
- SEASONS BIOTECHNOLOGY (TAIZHOU) CO LTDChinaActive DMF 31658 · latest filing May 2017
- TAPI NL BVNetherlandsActive DMF 31416 · latest filing Apr 2017
- Zhejiang Ausun Pharmaceutical Co., Ltd.China Company GMP cert on recordActive DMF 41152 · latest filing Apr 2025
- ZHEJIANG GUOBANG PHARMACEUTICAL CO., LTD. (No. 36 Kangyang Avenue)ChinaActive DMF 39273 · latest filing Dec 2023
- Zhejiang Huayi Pharmaceutical Co., Ltd.ChinaActive DMF 39288 · latest filing Feb 2024
- ZHEJIANG XIANFENG TECHNOLOGY GROUP CO LTDChinaActive DMF 41444 · latest filing Mar 2025
- Zydus Lifesciences LimitedIndia Company GMP cert on recordActive DMF 31463 · latest filing Apr 2017
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (13 listed products contain Macitentan). The latest listed patent expires 18 Oct 2029. The latest listed exclusivity runs to 28 Aug 2028. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Overview
Macitentan is an endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension (PAH). It works by preventing the vasoconstriction and proliferation effects of endothelin-1, a potent vasoconstrictor.
Chemical identity
- IUPAC name
- 5-(4-bromophenyl)-6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-N-(propylsulfamoyl)pyrimidin-4-amine
- Canonical SMILES
- CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br
- InChIKey
- JGCMEBMXRHSZKX-UHFFFAOYSA-N
- Synonyms
- Opsumit API, act 064992, act-064992, opsynvi component macitentan, opsumit
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Endothelin Receptor Antagonist
- Mechanism of action
- Endothelin Receptor Antagonists
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Macitentan?
14 organisations hold an active US FDA Type II Drug Master File or a CEP for Macitentan: Alembic Pharmaceuticals Limited (India), APITORIA PHARMA PRIVATE LTD (India), HONOUR LAB LTD (India), Laurus Labs Limited (India), MATRIX PHARMACORP PRIVATE LTD (India), MSN LIFE SCIENCES PRIVATE LIMITED (India), RAKS PHARMA PVT LTD (India) and SEASONS BIOTECHNOLOGY (TAIZHOU) CO LTD (China), and 6 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Macitentan Drug Master Files are active?
Alembic Pharmaceuticals Limited (DMF 31664), APITORIA PHARMA PRIVATE LTD (DMF 31749), HONOUR LAB LTD (DMF 31213), Laurus Labs Limited (DMF 31957), MATRIX PHARMACORP PRIVATE LTD (DMF 30969), MSN LIFE SCIENCES PRIVATE LIMITED (DMF 30212), RAKS PHARMA PVT LTD (DMF 31179) and SEASONS BIOTECHNOLOGY (TAIZHOU) CO LTD (DMF 31658) and 6 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
Does the FDA Orange Book list patents for products containing Macitentan?
Yes. The latest patent listed for an approved US product containing Macitentan expires 18 Oct 2029, across 13 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Macitentan supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Macitentan?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.